Know Cancer

forgot password

A Phase I and Pharmacokinetic Study of S-1 Combined With Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy

Phase 1
18 Years
Open (Enrolling)
Colorectal Neoplasm, Gastric Neoplasm, Secondary

Thank you

Trial Information

A Phase I and Pharmacokinetic Study of S-1 Combined With Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy

Dose level and escalating schedule are followings;

- S-1 (level 1/2, 3/4, 5/6: 60, 70, 80 mg/m2/day) every 12-h p.o. on days 1(evening)-15

- Irinotecan (level 1,2/3, 4/5, 6: 120, 130, 140, 150 mg/m2) mixed in d5w or normal
saline 500 ml iv over 90 min on day 1

- Oxaliplatin 85 mg/m2 fixed dose mixed in d5w 250 ml iv infusion over 2-h on day 1

Treatment will be administered every 3 weeks. Start at dose level 1. Thereafter, dose level
2, 3, 4, 5, and 6. If dose-limiting toxicity (DLT) occurs at dose level 1, dose level at -1
will follow

Dose escalation will be continued until more than one-third of the patients in a given
cohort show dose-limiting toxicity (DLT) during treatment cycle 1. At least three patients
will be enrolled in each cohort. Before escalating to the next dose level, all three
patients should have received at least one treatment cycle. If none of the first three
treated patients develops DLT in the first cycle at a specific dose level, dose escalation
will be continued. If one of the first three treated patients develops DLT at any dose
level, then three additional patients are to be entered on the same dose level. If only one
in six patients at a given level experiences a DLT, escalation will proceed. The MTD is
defined as the dose level at which at least one-third of patients experienced a DLT. The RD
for the subsequent phase II study is defined as the preceding dose level before the MTD is
attained. Intra-patient dose escalation will not be permitted. Treatment will be continued
in the absence of disease progression or unacceptable toxicity with maximum 12 cycles. For
purpose of determining the MTD, only DLT occurring during the first cycle of therapy will be

DLTs are defined as any of following;

- Grade 4 neutropenia lasting at least 7 days or grade 3 or 4 neutropenia associated with
fever  38.3C as single axillary temperature or 38 C for 1-h

- Grade 4 thrombocytopenia

- Grade 3 or 4 non-hematological toxicity except alopecia, and nausea/vomiting

- Grade 3 or 4 nausea/vomiting not reduced to grade 1 with aggressive antiemetic support

- Inability of the patient to take 75% of the planned chemotherapy dose during the
treatment period

Inclusion Criteria:

- Histologically or cytologically confirmed unresectable or metastatic colorectal or
gastric carcinoma

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Measurable disease, according to the RECIST criteria or non-measurable disease
Measurable lesions

- Previous adjuvant, palliative chemotherapy including 5-FU, oxaliplatin and
irinotecan, molecular targeted therapy and/or radiotherapy is allowed

- Adequate major organ functions

- Patients should sign a written informed consent before study entry

Exclusion Criteria:

- Prior history of peripheral neuropathy

- Inadequate cardiovascular

- Serious concurrent infection or nonmalignant illness

- Other malignancy within the past 3 years except non-melanomatous skin cancer or
carcinoma in situ of the cervix

- Psychiatric disorder that would preclude compliance

- Pregnant, nursing women or patients with reproductive potential without contraception

- Patients receiving a concomitant treatment with drugs interacting with S-1 such as
flucytosine, phenytoin, or warfarin et al.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Toxicity measured by NCICTC v.3

Outcome Time Frame:

During treatment

Principal Investigator

Kyung Hae Jung, M.D.Ph.D

Investigator Role:

Principal Investigator


Korea: Food and Drug Administration

Study ID:




Start Date:

September 2006

Completion Date:

December 2009

Related Keywords:

  • Colorectal Neoplasm
  • Gastric Neoplasm
  • Secondary
  • Gastrointestinal neoplasms
  • Combination chemotherapy
  • S-1
  • Irinotecan
  • Oxaliplatin
  • Neoplasms
  • Colorectal Neoplasms
  • Stomach Neoplasms